1. Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy
- Author
-
Laura Poupon-Bejuit, Amy Geard, Nathan Millicheap, Eridan Rocha-Ferreira, Henrik Hagberg, Claire Thornton, and Ahad A Rahim
- Subjects
GLP1-R Agonists ,Semaglutide ,Exendin-4 ,Neonatal Hypoxic-ischaemic Encephalopathy ,Neuroprotective Mechanisms ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Abstract Hypoxic-ischaemic encephalopathy (HIE) arises from diminished blood flow and oxygen to the neonatal brain during labor, leading to infant mortality or severe brain damage, with a global incidence of 1.5 per 1000 live births. Glucagon-like Peptide 1 Receptor (GLP1-R) agonists, used in type 2 diabetes treatment, exhibit neuroprotective effects in various brain injury models, including HIE. In this study, we observed enhanced neurological outcomes in post-natal day 10 mice with surgically induced hypoxic-ischaemic (HI) brain injury after immediate systemic administration of exendin-4 or semaglutide. Short- and long-term assessments revealed improved neuropathology, survival rates, and locomotor function. We explored the mechanisms by which GLP1-R agonists trigger neuroprotection and reduce inflammation following oxygen-glucose deprivation and HI in neonatal mice, highlighting the upregulation of the PI3/AKT signalling pathway and increased cAMP levels. These findings shed light on the neuroprotective and anti-inflammatory effects of GLP1-R agonists in HIE, potentially extending to other neurological conditions, supporting their potential clinical use in treating infants with HIE.
- Published
- 2024
- Full Text
- View/download PDF